COP vs JNJ: Which Is the Better Buy?
Side-by-side comparison of ConocoPhillips and Johnson & Johnson — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
ConocoPhillips · Energy
$122.55
-21.4% upside to fair value
Grade D
VS
Johnson & Johnson · Healthcare
$238.46
-11.8% upside to fair value
Med Conviction
Grade C+
QuantHub Verdict
JNJ has more upside to fair value
(-11.8%).
COP trades at a lower forward P/E
(19.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
COP |
JNJ |
| Current Price |
$122.55 |
$238.46 |
| Fair Value Estimate |
$96.36 |
$210.28 |
| Upside to Fair Value |
-21.4%
|
-11.8%
|
| Market Cap |
$149.8B |
$574.7B |
| Forward P/E |
19.3x
|
20.2x
|
| EV / EBITDA |
5.8x
|
13.3x
|
| Price / Sales |
2.5x
|
6.2x
|
| Price / FCF |
8.9x
|
29.4x
|
| Revenue Growth YoY |
+7.5%
|
+6.1%
|
| Gross Margin |
24.6%
|
72.8%
|
| Operating Margin |
19.6%
|
27.2%
|
| Return on Equity |
12.39%
|
32.87%
|
| Dividend Yield |
3.41% |
2.18% |
| FCF Yield |
10.9%
|
3.4%
|
| Analyst Consensus |
Buy
|
Moderate Buy
|
Investment Thesis
ConocoPhillips is the largest U.S. independent exploration and production company, operating approximately 2.4 million barrels of oil equivalent per day across its Lower 48, Alaska, Canada, and international segments. The company completed its transformative $22.5 billion Marathon Oil acquisition in late 2024 and is on track for $2 billion in cost synergies by the end of 2026. Full-year 2025 reve…
Johnson & Johnson is a high-quality healthcare conglomerate focused exclusively on Innovative Medicine and MedTech following the Kenvue spin-off. The company delivered $94.2B in FY2025 revenue with 6% operational growth, generated $19.7B in free cash flow, and guided for $99.5-100.5B in 2026 operational sales (above consensus). However, at $238 the stock trades at a P/S of 6.15x, well above the 5…
Accumulation Zones
| Metric |
COP |
JNJ |
| Zone Low |
$72.27 |
$157.71 |
| Zone High |
$81.91 |
$178.74 |
| In Buy Zone? |
No
|
No
|